Nuclear factor-KB provides an adaptive response to protect cancer cells against cytotoxicity induced by redox active therapeutics. RelB is uniquely expressed at a high level in prostate cancer with high Gleason scores. Recently, we showed that the level of RelB rapidly increases in androgen-independent prostate cancer cells after exposure to ionizing radiation (IR), leading to a reduction in intrinsic radiosensitivity. Here, we show that interaction of 1A,25-dihydroxyvitamin D 3 [1A,25-(OH) 2 D 3 ] with the vitamin D receptor significantly enhances radiosensitivity of prostate cancer cells at clinically relevant radiation doses. The radiosensitization effect of 1A,25-(OH) 2 D 3 is mediated, at least in part, by selectively suppressing IR-mediated RelB activation, leading to a reduced expression of its target gene MnSOD, a primary antioxidant enzyme in mitochondria. These results suggest that suppression of manganese superoxide dismutase is a mechanism by which 1A,25-(OH) 2 D 3 exerts its radiosensitization effect and that 1A,25-(OH) 2 D 3 may serve as an effective pharmacologic agent for selectively sensitizing prostate cancer cells to IR via suppression of antioxidant responses in mitochondria.
Introduction
Prostate cancer is the most common malignancy in North American countries and the second leading cause of cancer deaths in U.S. men (1) . Effective treatment options for the early stages of prostate cancer include surgery and localized radiation therapy. Androgen ablation therapy initially controls the advanced stages of the disease, but eventually, in nearly all patients, the disease develops to the more aggregative, androgen-independent prostate cancer forms that are resistant to hormone manipulations (2) . Although ionizing radiation (IR) is one of the most commonly used therapies to treat many malignancies, its therapeutic efficacy decreases when cancer cells develop adaptive responses to resist IR. Novel therapeutic strategies are therefore needed for the control of prostate cancer that have developed resistance to radiation therapy.
Epidemiologic data suggest that low exposure to sunlight and vitamin D deficiency may be risk factors for development of prostate cancer (3, 4) . Substantial experimental studies indicate that secosteroid hormone 1a,25-dihydroxyvitamin D 3 [1a,25-(OH) 2 D 3 ], the active form of vitamin D, exerts both antiproliferative and prodifferentiating effects in many normal and malignant cells including prostate cancer (5, 6) . The effects of 1a,25-(OH) 2 D 3 on the growth of human prostate cancer cells vary widely. For example, LNCaP, an androgen-dependent prostate cancer cell line, is responsive to 1a,25-(OH) 2 D 3 (7, 8) . Androgen-independent prostate cancer cell lines, such as PC-3 cells, are generally less responsive (9, 10) , whereas vitamin D receptor (VDR) -deficient prostate cancer cell line DU-145 exhibits no change in expression of antiapoptotic proteins when exposed to 1a,25-(OH) 2 D 3 (11). The biological actions of 1a,25-(OH) 2 D 3 are primarily mediated by the VDR that binds to the VDR response elements either alone or by forming heterodimers with a retinoid X receptor, resulting in regulation of target genes (12) . Several mechanisms have been proposed for the antiproliferative effect of 1a,25-(OH) 2 D 3 in prostate cancer cells, including promotion of cell cycle arrest, induction of apoptosis, inhibition of growth factor, and modulation of kinase pathways (11, 13 -18) . However, the precise molecular mechanism(s) associated with the antiproliferative effects of 1a,25-(OH) 2 D 3 is not fully elucidated.
Reactive oxygen species -mediated nuclear factor-nB (NF-nB) activation has been implicated in radiation resistance of cancers (19 -21) . It has been shown that NF-nB activation confers to cancer cells a resistance to IR-induced cell death by up-regulating antiapoptotic proteins, such as bcl-2, bcl-xl (22 -24) . NF-nB is composed of homodimers or heterodimers formed by five family members [e.g., RelA (p65), RelB, c-Rel, NF-nB1 (p50/p105), and NF-nB2 (p52/ p100)]. The NF-nB dimers are inactive when bound by InB inhibitors in cytoplasm. Transactivation of NF-nB is mediated by targeting InB through phosphorylation, ubiquitination, and degradation by proteasome after exposure to many types of stimuli including IR (25) . Lessard et al. (26) showed recently that the nuclear localization of RelB correlates to a prostate cancer patient's Gleason scores. This clinical finding is consistent with our recent study, which showed that IR induces RelB activation in androgen-independent prostate cancer PC-3 cells (27) . In the present study, we show that 1a,25-(OH) 2 Thus, our results provide a potential approach for enhancing the radiosensitivity of androgen-independent prostate cancer using 1a,25-(OH) 2 D 3 coupled to an inhibition of the antioxidant response mechanism and identify mitochondria as a target for the radiosensitization effect of 1a,25-(OH) 2 D 3 in prostate cancer cells.
Materials and Methods

Cell Culture and Treatments
This study used human prostate carcinoma/adenocarcinoma cell lines, including LNCaP and PC-3 and DU-145, which were obtained from the American Type Culture Collection. American Type Culture Collection's recommended media were used to grow and maintain the appropriate cell lines. 1a,25-(OH) 2 D 3 was purchased from Sigma and dissolved in ethanol at a concentration of 10 À2 mol/L. The cultured cells were pretreated with 1a,25-(OH) 2 D 3 by replacing the media containing 1a,25-(OH) 2 D 3 at concentrations of 10 À10 to 10 À5 mol/L or with ethanol as a control followed by irradiation treatment using a 100 kV X-ray machine (Philips) at a range of 0.5 to 6 Gy.
Cell Survival Analyses For colony survival analyses, the cells were plated in sixwell plates at low densities and then pretreated with 1a,25-(OH) 2 D 3 for 24 h before radiation treatment. The cells were cultured until colonies formed. The colonies were washed with 1Â PBS and stained with a crystal violet dye. The surviving fraction was calculated as the ratio of the number of colonies formed to the number of cells efficiently plated. Trypan blue exclusion assay was used to determine the effects of transfected RelB and VDR short interference RNA (siRNA) on radiosensitization. The cells were plated at a concentration of 10 5 cells per well. After treatment, the cells were stained with a 0.4% trypan blue dye and counted using a Vi-Cell cell viability analyzer (Beckman Coulter). Plasmid Construction and Cell Transfection To study the role of NF-nB in radiosensitization of prostate cancer cells, tandem ligations of four NF-nB motifs were cloned between SacI and XhoI sites of SV40/pGL3 (Promega). Sequences of NF-nB oligonucleotides tagged with SacI and XhoI at their terminals were 5 ¶-CAGTTGAGGG-GACTTTCCCAGGC-3 ¶ (upper strand) and 5 ¶-TCGAGGC-CTGGGAAAGTCCCCTCAACTGAGCT-3 ¶ (lower strand). The construct contains multiple NF-nB elements upstream of the SV40 promoter-driven luciferase reporter. The generated construct was cotransfected into 1a,25-(OH) 2 D 3 -pretreated or unpretreated PC-3 cells with a h-galactosidase expression construct using LipofectAMINE (Invitrogen) according to the manufacturer's protocol. Transfected cells were treated with IR at 6 Gy. Luciferase and h-galactosidase activities were measured as described previously (28) . In addition, expression constructs for the human RelB gene (American Type Culture Collection) and siRNA for targeting RelB and VDR (Santa Cruz Biotechnology) were transfected to modulate their expression levels in the PC-3 cells.
NF-KB Binding Assay Nuclear extracts from the treated or untreated PC-3 cells were prepared as described previously (29) . Binding activities of five members of the NF-nB family were measured using an ELISA-based TransAM NF-nB Family kit (Active Motif) according to the manufacturer's protocol.
Chromatin Immunoprecipitation A ChIP-IT system (Active Motif) was used to study 1a,25-(OH) 2 D 3 -mediated transcriptional regulation, according to the manufacturer's protocol. PC-3 chromatin was pulled down using a p50 antibody, and the NF-nB enhancer region of the MnSOD gene was quantified by PCR. PCR primer sequences were 5 ¶-CGGGGTTATGAAATTTGTTGAGTA-3 ¶ (upper strand) and 5 ¶-CCACAAGTAAAGGACTGAAAT-TAA-3 ¶ (lower strand). The MnSOD exon 2 was amplified as an untargeted control. Primer sequences were 5 ¶-TGAC-CGGGCTGTGCTTTCTCG-3 ¶ (upper strand) and 5 ¶-ACTG-CCTCCCGCCGCTCAGCC-3 ¶ (lower strand). In addition, Western blots were done to quantify RelB in the chromatin immunoprecipitation preparations.
ReverseTranscription-PCR mRNA was isolated from the treated and untreated PC-3 cells using a Micro-FastTrack 2.0 mRNA Isolation kit (Invitrogen) and then analyzed using a SuperScript First-Strand Synthesis System for reverse transcription-PCR (RT-PCR; Invitrogen) with gene-specific primers. Primers for amplification of the human RelA and RelB genes were purchased from Santa Cruz Biotechnology. Primers for MnSOD were 5 ¶-AGCATGTTGAGCCGGGC-AGT-3 ¶ (forward) and 5 ¶-AGGTTGTTCACGTAGGCCGC-3 ¶ (reverse); primers for bcl-xl were 5 ¶-CCCAGAAAGG-ATACAGCTGG-3 ¶ (forward) and 5 ¶-GCGATCCGACT-CACCAATAC-3 ¶ (reverse); and primers for h-actin were 5 ¶-TGATGATATCGCCGCGCTCGTCGT-3 ¶ (forward) and 5 ¶-CACAGCCTGGATAGCAACGTACAT-3 ¶ (reverse).
RNA Interference siRNA was used to selectively knock down RelB or VDR in PC-3 cells. siRNA targeting RelB or VDR (0.1 Amol/L) was transfected into the PC-3 cells using LipofectAMINE 2000 within a serum-reduced Opti-MEM (Invitrogen) and followed by 6 Gy IR treatment. Reduction of RelB and VDR and effects on radiosensitization in the cells were quantified by Western blots and trypan blue exclusion assay, respectively.
Immunoblotting Analysis Total cellular extracts were prepared from treated and untreated PC-3 cells as described previously (27) . To quantify levels of the NF-nB family and its target gene, 100 Ag of cellular extracts were fractionated by a SDS-PAGE, 8% (w/v) polyacrylamide gel, and then transferred onto a nitrocellulose membrane and blotted with antibodies to RelA, RelB, MnSOD, bcl-x, 24-hydroxylase (CYP24), and h-actin. With the exception of the MnSOD antibody obtained from Upstate Biotechnology, all antibodies were purchased from Santa Cruz Biotechnology. A goat antirabbit IgG-horseradish peroxidase -conjugated secondary antibody (Santa Cruz Biotechnology) was used to detect all proteins with the exception that a goat anti-mouse IgGhorseradish peroxidase -conjugated secondary antibody (Santa Cruz Biotechnology) was used to detect h-actin. Immunoblots were visualized by an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).
SOD Activity Gels To quantify MnSOD activity, 100 Ag of cellular extracts were separated on SDS-PAGE gels. After electrophoresis, the gels were stained with 2.3 mmol/L nitroblue tetrazolium solution for 20 min and with 280 mmol/L TEMED solution for 15 min. After washing with distilled water, SOD activity bands were detected by exposing the gels to fluorescent light.
Quantitative and Statistical Data Analyses
Multiple independent experiments were done. Data of PCR, RT-PCR, Western blots, and SOD activity were quantified using an imaging quantitative software, Quantity One (Bio-Rad). Statistical significances between treatments and controls were analyzed using one-way ANOVA À8 to 10 À6 mol/L were added to the media, significant toxicity of PC-3 cells does not occur, but their radiation sensitivity is enhanced (Fig. 1A) . Because the levels of 1a,25-(OH) 2 D 3 added to the media may have been excessive, we determined 1a,25-(OH) 2 D 3 remaining in media after 7 days of incubation. As shown in Fig. 1B , the majority of 1a,25-(OH) 2 D 3 was found in the media portions. It has been shown that the major 1a,25-(OH) 2 D 3 catabolic enzyme, CYP24, can be induced in prostate cancer cells, leading to a reduction of 1a,25-(OH) 2 D 3 antiproliferative effects (30, 31) . Our finding that 1a,25-(OH) 2 D 3 enhances CYP24 levels in PC-3 cells in a dose-dependent manner (Fig. 1B) agrees with earlier studies. Our results suggest that biological levels of 1a,25-(OH) 2 D 3 effectively enhance radiation sensitivity of prostate cancer cells at a level 10-fold lower than the amount added to the media. Because PC-3 has functional VDR and represents a radiation-resistant androgen-independent prostate cancer, it was used in subsequent experiments as a model cell line to investigate the molecular mechanism for 1a,25-(OH) 2 D 3 -mediated radiosensitization.
1A,25-(OH) 2 D 3 Inhibits RelB Expression in Prostate Cancer Cells NF-nB activation has been implicated in resistance to IR in many types of cancer including prostate cancer (19 -21) . As an initial step to examine whether 1a,25-(OH) 2 D 3 -induced radiosensitization is mediated through suppression of IR-induced NF-nB activation, a NF-nBdriven luciferase reporter plasmid was used as a probe. The results show that NF-nB elements are necessary for IR-induced luciferase activity but that radiation-induced NF-nB activation was abolished by 1a,25-(OH) 2 D 3 ( Fig. 2A) (Fig. 2B) . To further verify the effect of 1a,25-(OH) 2 D 3 on NF-nB family members, a NF-nB binding assay was done for all known members of the NF-nB family. An oligonucleotide containing NF-nB consensus sequence was bound with nuclear extracts from the treated and untreated PC-3 cells and then incubated with antibodies against each of the five NF-nB family members. The binding activities were quantified by ELISA assay. The results confirm that IR can activate all members of the NF-nB family, with the exception of c-rel, in PC-3 cells. Importantly, 1a,25-(OH) 2 D 3 selectively blocks IR-induced RelB activation (Fig. 2C) . These results suggest that RelB activation may be a major contributor to NF-nB-mediated radiation resistance in prostate cancer cells and that 1a,25-(OH) 2 D 3 enhances radiosensitization through selectively suppressing RelB activation.
Reduction of RelB Is Critical for 1A,25-(OH) 2 D 3Ê nhanced Radiosensitization
RelB is a member of the NF-nB family that is associated with advanced stages of prostate cancer (26) . To verify that 1a,25-(OH) 2 D 3 selectively suppresses RelB expression leading to enhanced radiosensitization, three approaches were used. Because 1a,25-(OH) 2 D 3 exerts its cytotoxic effect via VDR, in the first approach, a VDR siRNA was transfected into the 1a,25-(OH) 2 D 3 -pretreated PC-3 cells to selectively knock down expression of VDR. As expected, VDR siRNA-transfected cells become resistant to IR (Fig. 3A) . Western blots confirmed that expression of VDR is reduced by the targeted siRNA but not by the siRNA control. Consistent with reduced VDR, the level of RelB is increased in the siRNA-targeted cells (Fig. 3B) . In the second approach, RelB was overexpressed in PC-3 cells. The human RelB gene is driven by the cytomegalovirus promoter that lacks a VDR element; thus, expression of RelB by this construct is not affected by 1a,25-(OH) 2 D 3 . Cell viability of transfected cells shows that the increased RelB confers cellular resistance to IR compared with the vector only control (Fig. 4A) . Western blots confirmed that RelB is ectopically expressed in 1a,25-(OH) 2 D 3 -pretreated PC-3 cells but is not reduced by 1a,25-(OH) 2 D 3 (Fig. 4B ). In the third approach, to further establish the role of RelB in mediating 1a,25-(OH) 2 D 3 -enhanced radiosensitization, we did experiments using siRNA-based knocked-down RelB in the presence and absence of 1a,25-(OH) 2 D 3 . RelB siRNA was transfected into 1a,25-(OH) 2 D 3 -pretreated or untreated PC-3 cells and then treated with IR. Similar to the effect of 1a,25-(OH) 2 D 3 treatment, the siRNA-based down-regulation of RelB expression enhances radiosensitization (Fig. 5A) . Western blots verified that the transfected RelB siRNA significantly reduces RelB expression levels in both 1a,25-(OH) 2 D 3 -pretreated and unpretreated cells (Fig. 5B) . The combined suppressive effects of siRNA targeting and 1a,25-(OH) 2 D 3 result in the lowest RelB expression level in Reactive oxygen species -induced toxicity has been implicated in IR-mediated cell death (19 -21) . An important mitochondrial antioxidative protein, MnSOD, is rapidly induced by reactive oxygen species through NFnB -mediated transcriptional activation (27, 28) . To identify RelB target genes responsible for the 1a,25-(OH) 2 D 3 -enhanced radiosensitization, we examined the effects of RelB on the transcription of the human MnSOD gene. Chromatin immunoprecipitation assay was done to detect RelB binding to the intronic NF-nB enhancer region of the gene. A p50 antibody was used to precipitate chromatin, and DNA was analyzed by PCR using the gene-specific primers. The results shown in Fig. 6A indicate that IR increases the amount of the enhancer region pulled down by the p50 antibody, but pretreatment with 1a,25-(OH) 2 VD 3 reduces the PCR products. As an internal control, a transcription factor IIB -associated glyceraldehyde-3-phosphate dehydrogenase promoter fragment was precipitated by the transcription factor IIB antibody, which was not affected by the treatments. A fragment (459 -612) located in the MnSOD exon 2 was amplified as an untargeted control and chromatin pulled down by an IgG served as a negative antibody control. The expected fragments were amplified using input DNA templates, and no PCR product was observed from these controls. In addition, Western blots showed that the amount of RelB in chromatin is increased by IR but reduced by 1a,25-(OH) 2 D 3 , whereas the IgG control does not respond to the treatments.
To verify that MnSOD is a major RelB target involved in the modulation of radiosensitization by 1a,25-(OH) 2 D 3 , mRNA and cellular proteins were extracted from PC-3 cells after treatments and then quantified by RT-PCR using the gene-specific primers and by Western blots with the proteinspecific antibodies. To further verify that the effect of 1a,25-(OH) 2 D 3 on MnSOD suppression leads to a reduction of MnSOD activity, the same amounts of cellular extracts used for Western blots were also quantified by analysis of SOD activity gels. The results, shown in the three panels of Fig. 6B , are consistent with that IR significantly induces MnSOD expression but is blocked by 1a,25-(OH) 2 D 3 , whereas bcl-xl is less responsive to the treatment, suggesting that MnSOD is a major target of RelB in response to IR. Thus, removal of MnSOD induction by 1a,25-(OH) 2 D 3 likely facilitates radiosensitization, as shown in Fig. 6C .
Discussion
NF-nB has been shown to respond rapidly to a variety of stimuli by selectively activating prosurviving genes to prevent stimulus-induced apoptosis (32) . In general, cancer cells express high levels of constitutive NF-nB compared with their normal counterparts (33) . Importantly, NF-nB transactivation is induced in many types of cancer by therapeutics including radiation (21, 34, 35) . Thus, inhibition of the NF-nB pathway is being used to search for novel anticancer drugs that selectively kill tumor cells. Accumulated evidence shows that combinations of certain effective NF-nB inhibitors with conventional radiotherapeutic or chemotherapeutic treatments can improve the efficiency of standard therapies (34 -36) . Studies to inhibit NF-nB as a means to enhance cancer therapy have traditionally focused on the canonical dimer p50/RelA because it is the best-known dimer of the NF-nB family for being responsive to cytokine-mediated NF-nB transactivation. In fact, inhibition of p65 and ablation of InB kinase h are beneficial for enhancing chemosensitivity and radiosensitivity, respectively (35, 37, 38) . However, among NF-nB family members, the nuclear level of RelB in prostate cancer patients correlates with Gleason scores (26) . Recently, we showed that the noncanonical dimer p52/RelB is more important in protecting prostate cancer cells against IR than p50/RelA is (27) . The present study extends our previous findings to show that IR induces RelB in prostate cancer cells to a greater extent than other members of the NF-nB family and that 1a,25-(OH) 2 D 3 selectively inhibits radiation-induced RelB in prostate cancer cells. Thus, 1a,25-(OH) 2 D 3 may be effective for enhancing the susceptibility of prostate cancer cells with high Gleason scores to IR. 1a,25-(OH) 2 D 3 , a member of a steroid hormone family, is known to regulate calcium homeostasis and bone formation. Several studies have shown its significant antiproliferative activity when administered to several types of cancer in vitro and in vivo (5, 6, 39, 40) . In particular, the association between vitamin D deficiencies with prostate carcinogenesis has provided a rational basis for clinical trials to use 1a,25-(OH) 2 D 3 and its analogues in the control of prostate cancer (40, 41) . However, little is known about the potential effect of 1a,25-(OH) 2 D 3 on sensitization of prostate cancer cells to radiation therapy. 1a,25-(OH) 2 D 3 exerts its biological actions through nuclear receptordependent ligand transcriptional regulation of target genes. Our results, which indicate that androgen-dependent prostate cancer LNCaP cells with a high level of VDR are sensitive to both 1a,25-(OH) 2 D 3 and IR, are consistent with our previous studies that showed lower levels of RelB and MnSOD in LNCaP cells than in androgen-independent Figure 6 . 1a,25-(OH) 2 D 3 -mediated suppression of RelB target genes. A, chromatin from the treated and untreated PC-3 cells was precipitated using p50, transcription factor IIB (TFIIB ), or IgG antibody. The NF-nB enhancer region of the human MnSOD gene was analyzed by PCR (top ). Fragments of the exon 2 of the human MnSOD gene and the glyceraldehyde-3-phosphate dehydrogenase promoter region were amplified as an untargeted control and an internal control, respectively. IgG-precipitated product served as a negative antibody control. RelB in the precipitated chromatin was measured by Western blots normalized with IgG (bottom ). B, 24 h after treatment, mRNA and total proteins from the untreated or treated PC-3 cells were quantified for expression levels of MnSOD and bcl-xl by RT-PCR (top ), by Western blots (middle), and by SOD activity gel (bottom ). The expression levels of the target genes shown in RT-PCR and Western blots were normalized by h-actin. MnSOD activity was compared with copper/zinc SOD (Cu-ZnSOD ) activity. PCR products of the MnSOD enhancer region and RelB amounts in (A) and expression of MnSOD shown in the three panels of (B) were normalized by the relating controls, and fold increases or decreases were calculated by normalizing amounts in the treated groups with the untreated controls as described in prostate cancer cells (27) (44, 45) . Alternative routes of administration have been used in patients with hepatocellular carcinoma (46) . Although the effectiveness of regional administration of 1a,25-(OH) 2 D 3 remains to be proven, it is interesting to note that the prostate is one organ most amendable to such an approach. These possibilities, coupled to our finding that the radiosensitization effect of 1a,25-(OH) 2 D 3 is, at least in part, mediated by the suppression of RelB, suggest that further development of vitamin D analogues that can effectively block RelB transcription may be particularly useful for radiosensitization of radiation-resistant prostate cancer cells.
We have shown previously that activation of NF-nB is important for induction of MnSOD, a primary antioxidant enzyme that removes superoxide radicals generated in mitochondria (28, 47) . Our previous results show that RelB plays an important role in IR-induced MnSOD expression in prostate cancer cells (27) . It has been reported that 1a,25-(OH) 2 D 3 transcriptionally represses the human and mouse RelB genes through interaction with VDR that specifically binds to VDR response elements located in the RelB promoter regions (48, 49) . The results from the present study further show that 1a,25-(OH) 2 VD 3 represses IR-induced RelB transcription leading to suppression of RelB-mediated radioprotection. Together, these findings identify a potential approach to enhance the efficacy of IR therapy in prostate cancer cells by targeting RelB. As depicted in Fig. 6C , IR activates NF-nB members, RelB in particular, leading to induction of MnSOD and resulting in protection against IR-induced cell death. 1a,25-(OH) 2 D 3 acts to repress RelB transcription through interaction with VDR that binds to VDR response elements. Down-regulation of RelB by 1a,25-(OH) 2 VD 3 , in turn, blocks RelB-mediated MnSOD induction by IR.
In addition to MnSOD, bcl-xl, a NF-nB target antiapoptotic protein, whose response is widely thought to be involved in both chemoresistance and radioresistance (22 -24) , is also changed by modulating RelB level in cells. However, our results suggest that induction of bcl-xl may not be the primary response to IR. Response to IR occurs in MnSOD as early as 3 h after IR treatment, but in bcl-xl, response is detectable after 12 h (data not shown). It is possible that IR induces expression of MnSOD and bcl-xl in prostate cancer cells to sequentially protect the cells against IR. The ability of MnSOD to remove reactive oxygen species necessitates a rapid induction of MnSOD by IR, whereas the function of bclxl to inhibit apoptosis initiated by reactive oxygen species renders further protection. Because apoptosis is not the main mechanism for the death of cancer cells in response to radiation (50) , inhibition of MnSOD may participate in the reduction of primary and/or secondary adaptive responses by IR, which could efficiently enhance the efficacy of radiotherapy.
